Laura Bartoli

Florence, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 29 publications

Is my smartwatch a valid witness? A systematic review and meta-analysis.

Is my smartwatch a valid witness? A systematic review and meta-analysis.

Journal: Forensic science international

Published: November 29, 2025

Defining innovativeness of high-technology medical devices in an Italian region.

Defining innovativeness of high-technology medical devices in an Italian region.

Journal: European journal of hospital pharmacy : science and practice

Published: January 22, 2022

"Real-world" endovascular versus surgical arteriovenous fistula economic evaluation: Can clinical outcomes and use of resources be derived from different countries?

"Real-world" endovascular versus surgical arteriovenous fistula economic evaluation: Can clinical outcomes and use of resources be derived from different countries?

Journal: The journal of vascular access

Published: July 23, 2021

Medical therapy, radiofrequency ablation or cryoballoon ablation as first-line treatment for paroxysmal atrial fibrillation: interpreting efficacy through restricted mean survival time and network meta-analysis.

Medical therapy, radiofrequency ablation or cryoballoon ablation as first-line treatment for paroxysmal atrial fibrillation: interpreting efficacy through restricted mean survival time and network meta-analysis.

Journal: Reviews in cardiovascular medicine

Published: July 11, 2021

Simplified figure to present direct and indirect comparisons: Revisiting the graph 10 years later.

Simplified figure to present direct and indirect comparisons: Revisiting the graph 10 years later.

Journal: World journal of methodology

Published: March 19, 2021

SARS-COV-2 pandemic: establishing three risk levels for 19 Italian regions and two autonomous provinces.

SARS-COV-2 pandemic: establishing three risk levels for 19 Italian regions and two autonomous provinces.

Journal: European journal of hospital pharmacy : science and practice

Published: February 09, 2021

Letter by Ferracane et al Regarding Article, "Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials".

Letter by Ferracane et al Regarding Article, "Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials".

Journal: Circulation

Published: February 08, 2021

First-line treatments for chronic lymphocytic leukemia: Analysis of 7 trials based on the restricted mean survival time.

First-line treatments for chronic lymphocytic leukemia: Analysis of 7 trials based on the restricted mean survival time.

Journal: International journal of clinical pharmacology and therapeutics

Published: December 10, 2020

Chimeric antigen receptor T-cell (CART) therapy in non-Hodgkin's lymphoma: the survival gain improves as more mature follow-up data become available.

Chimeric antigen receptor T-cell (CART) therapy in non-Hodgkin's lymphoma: the survival gain improves as more mature follow-up data become available.

Journal: European journal of hospital pharmacy : science and practice

Published: December 01, 2020

Restricted mean survival time in patients with chronic lymphocytic leukemia treated with chemotherapy-free regimens as first line.

Restricted mean survival time in patients with chronic lymphocytic leukemia treated with chemotherapy-free regimens as first line.

Journal: Leukemia & lymphoma

Published: November 10, 2020

Implant-based breast reconstruction: re-analysis of the odds ratio for skin flap necrosis.

Implant-based breast reconstruction: re-analysis of the odds ratio for skin flap necrosis.

Journal: Breast cancer research and treatment

Published: September 25, 2020

The Restricted Mean Survival Time as a Tool for Ranking Comparative Outcomes in a Narrative Review that Evaluates a Network of Randomized Trials: An Example Based on PCSK9 Inhibitors.

The Restricted Mean Survival Time as a Tool for Ranking Comparative Outcomes in a Narrative Review that Evaluates a Network of Randomized Trials: An Example Based on PCSK9 Inhibitors.

Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions

Published: September 22, 2020

Showing 1-12 of 29

Last Updated: 09/26/2026